India overtakes China, Israel in key US billionaires list; Jay Chaudhry richest Indian-American
Forbes reported that there are a total of 125 foreign-born American citizens who currently live in the United States, on its billionaires list. The tally was at 92 in 2022. The publication adds that these immigrants come from 43 countries and 'account for 14% of the country's nearly 900 three-comma fortunes'.
Read More: Elon Musk picks fight with several Trump allies hours after Linda Yaccarino steps down as X CEO
'These American immigrants are worth a record $1.3 trillion combined and hold 18% of America's $7.2 trillion in total billionaire wealth,' Forbes noted.
India (7) was behind Israel, Canada, and on par with China in terms of origin for billionaire immigrants in 2022. However, New Delhi now leads the list with 12. Israel (11) and Taiwan (11) are next in the 2025 list. China had seven in 2022 and eight in 2025.
Read More: US launches $250 Visa Integrity Fee: Will Trump's latest move impact Indian tourists, students, H-1B workers?
The Forbes list highlights Indian-Americans like Jay Chaudhry, Sundar Pichai, and Vinod Khosla (Khosla Ventures) as prominent Indian-origin billionaires. Overall, the richest immigrant in the United States is Tesla and SpaceX boss Elon Musk, who is also the richest man in the world with a whopping net worth of nearly $400 billion.
Musk was born in South Africa and came to the US via Canada as a college student. Google co-founder Sergey Brin is the second richest immigrant, with an estimated $139.7 billion fortune, according to Forbes. Three of the 10 richest people in America (and the world) are immigrants.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Economic Times
7 minutes ago
- Economic Times
India should avoid rushing for trade pact with US, warn experts
Synopsis Experts caution India against rushing into a trade deal with the US, potentially compromising crucial sectors like agriculture. The US's aggressive tactics, including imposing tariffs on key partners like the EU, highlight the risk of unbalanced agreements. Despite US pressure, many nations resist one-sided terms, urging India to proceed cautiously and protect its core interests during negotiations. Getty Images India should avoid rushing into a trade deal with the US that compromises core sectors like agriculture, experts on Sunday said, cautioning that Washington is not sparing even its key partners like the EU. The US has shot off letters to 24 countries and the European Union (EU) imposing tariffs that are as high as 50 per cent on Brazil. On its key trading partners like the EU and Mexico, 30 per cent duties have been proposed from August 1. Economic think tank GTRI (Global Trade Research Initiative) said India must recognise that it is not alone in facing US pressure. The US is currently negotiating with over 20 countries and seeking concessions from more than 90. "Yet most are resisting because they see these MASALA (Mutually Agreed Settlements Achieved through Leveraged Arm-twisting) deals for what they are politically driven, transactional demands offering no lasting trade certainty," GTRI Founder Ajay Srivastava said. He added that both the EU and Mexico are major trade partners of the US, and Washington can impose tariffs on them to pressure them into quick deals, India cannot expect a balanced deal. Another trade expert said India should tread cautiously while negotiating the trade pact with the US. The expert added that Trump's trade threat is rapidly losing credibility as despite more than three months of pressure, only two countries -- the UK and Vietnam -- have agreed to the USA's one-sided terms. From Japan and South Korea to the EU and Australia, countries are resisting Trump's trade deals that demand tariff cuts without reciprocal US concessions, mandate guaranteed purchases of American goods, and leave the door open for future tariffs even after a deal is signed, the GTRI said. A team of Indian trade negotiators will soon visit Washington to further talks for the proposed Bilateral Trade Agreement (BTA). "India should stay the course and avoid trading away core sectors like agriculture. A hasty deal under pressure could have irreversible consequences, especially when such agreements may not survive the next shift in US politics," Srivastava said.
Hindustan Times
10 minutes ago
- Hindustan Times
Trump Says 200% Pharma Tariffs Are Coming. Wall Street Shrugs.
But since Tuesday, when Donald Trump said in a cabinet meeting that imported pharmaceuticals would face a massive levy, investors have been cautiously celebrating. Despite a broad stock selloff on Friday, the NYSE Arca Pharmaceutical Index is up around 1% over the past week, compared with a basically flat performance for the S&P 500. That outperformance may seem puzzling, but for Wall Street, the size of the tariff matters less than the timing. The 200% figure lit up cable news chyrons, but investors focused instead on the grace period Trump floated. 'We're going to give people about a year, year and a half to come in, and after that, they're going to be tariffed,' he said. A year and a half is a long runway—and it could turn out to be even longer in practice. In a note titled 'Tariffs Schmariffs,' Jefferies analyst Akash Tewari argues that if the grace period begins some time this year and lasts for a year and a half, companies could continue importing drugs tariff-free until 2027. They could buy even more time if they stockpile during that period to cover demand at least until some time in 2028. That might give them time to build entirely new U.S. manufacturing facilities, which typically takes around four years. This doesn't mean Trump isn't getting what he wants. After all, the tariffs are meant as a threat to push companies to make more of their products in the U.S. And in this case, the threat seems to be working. Since Trump began threatening pharma with tariffs, the industry has moved on two fronts. First, companies have been stockpiling drugs at a furious pace to build a cushion. For instance, the Wall Street Journal reported last month that $36 billion worth of hormone treatments—used in popular obesity and diabetes drugs—have been shipped from Ireland this year, more than double last year's total. Second, the industry has announced major investments in U.S. manufacturing. Some of that may be political posturing, but much of it reflects a real shift. Companies increasingly see no choice but to bring production back, at least for drugs sold to American patients. Eli Lilly, for example, has announced a $27 billion plan to expand manufacturing in the U.S. Making drugs in the U.S.—and registering the intellectual property here—comes with a tax hit. That is a big reason the industry offshored production to low-tax countries like Ireland in the first place. But Trump's 'Big Beautiful Bill' offers some relief to offset the pain. The bill lets companies immediately deduct R&D expenses and equipment purchases and raises the cap on how much interest they can write off—making it a lot cheaper to build new plants at home. The upshot: with more time to prepare and a friendlier tax environment, pharma companies may barely feel the sting of tariffs. Take Merck. The company plans to produce a new version of its blockbuster drug Keytruda in the U.S. Jefferies estimates that with steps like stockpiling, gradually shifting production and trimming some costs, the hit to Merck's earnings from tariffs in 2027 and 2028 could be just 1% to 2%. That is actually better than Jefferies's earlier model for a smaller 25% tariff, which assumed fewer workarounds. The sense of a new normal settling in around Trump's second presidency might help explain why dealmaking has returned to the sector. Merck this past week announced a roughly $10 billion deal to buy Verona Pharma. That followed a series of other deal announcements, including Eli Lilly's $1.3 billion pact to acquire Verve Therapeutics. By the end of Trump's term, the U.S. pharmaceutical supply chain could look very different, with a greater share of innovative drug production happening on American soil. That would be a rare win-win—for the White House and for the industry. Write to David Wainer at
Time of India
18 minutes ago
- Time of India
Violence in name of language is dangerous: Maya
1 2 Lucknow: BSP national president Mayawati on Sunday said that the dispute and violence happening over language all over the country, especially in Maharashtra and Tamil Nadu, is "dangerous". "Mumbai is the economic capital of the country, with which people from all states have a direct contact. The govt must guarantee the safety of people's lives, property, and religion. The central govt should also take interest in this," she said She added that such disputes take place when narrow politics of religion, region, caste and language tries to dominate patriotism and love for the country. "Every Indian should work with pride in being Indian," she said. Mayawati reviewed the preparations of the party organisation in seven states: Maharashtra, Gujarat, Telangana, Andhra Pradesh, Karnataka, Tamil Nadu and Kerala. She issued directions to party members to work towards increasing the mass base of the party in these states. She said that all the state govts should pay special attention to important issues of public interest like law and order, inflation, poverty, unemployment, illiteracy, and health, so that national interest is not affected. by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like Is it legal? How to get Internet without paying a subscription? Techno Mag Learn More Undo She also talked about incidents of bridge collapse and other infrastructure-related accidents, and said that incidents like these in various states of the country and the huge loss of life and property due to them shake the faith of people. Taking cognisance of the continuous political factionalism and conflict-induced instability within the Congress party and govt in Karnataka, just like the previous BJP govt, Mayawati said, "It is affecting the rule of law and the poor and downtrodden people are becoming its victims. Although there are govts of different parties in Telangana, Andhra Pradesh, Tamil Nadu and Kerala, the situation is no different. "
